Combination amphotericin B-rifampin therapy for pulmonary aspergillosis in a leukemic patient.
Pulmonary aspergillosis developed in a 62-year-old man with acute myelogenous leukemia. Therapy with amphotericin B and 5-fluorocytosine was begun. Synergy between amphotericin B and rifampin was demonstrated in vitro, and therapy with firampin replaced 5-fluorocytosine. Progressive clearing of the pulmonary lesion ensued, suggesting in vivo efficacy as well. Further studies of patients utilizing this regimen are warranted.
D000666:Amphotericin B / Q000627:therapeutic use*; D001228:Aspergillosis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001232:Aspergillus fumigatus / Q000302:isolation & purification; D004357:Drug Synergism; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D008172:Lung Diseases, Fungal / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011859:Radiography; D012293:Rifampin / Q000627:therapeutic use*
D000666:Amphotericin B; D005437:Flucytosine; D012293:Rifampin